The estimated Net Worth of Colin Love is at least 20.3 百万$ dollars as of 16 May 2024. Dr Love owns over 17,615 units of Replimune Inc stock worth over 8,061,068$ and over the last 6 years he sold REPL stock worth over 12,256,087$.
Dr has made over 19 trades of the Replimune Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 17,615 units of REPL stock worth 113,969$ on 16 May 2024.
The largest trade he's ever made was selling 30,000 units of Replimune Inc stock on 15 October 2021 worth over 901,800$. On average, Dr trades about 16,689 units every 68 days since 2018. As of 16 May 2024 he still owns at least 777,345 units of Replimune Inc stock.
You can see the complete history of Dr Love stock trades at the bottom of the page.
Dr. Colin A. Love is the Chief Operating Officer at Replimune Inc.
Dr Love is 62, he's been the Chief Operating Officer of Replimune Inc since . There are 1 older and 7 younger executives at Replimune Inc. The oldest executive at Replimune Group Inc is Dr. Colin A. Love Ph.D., 63, who is the Chief Operating Officer.
Colin's mailing address filed with the SEC is C/O REPLIMUNE GROUP, INC., 500 UNICORN PARK DRIVE, SUITE 303, WOBURN, MA, 01801.
Over the last 6 years, insiders at Replimune Inc have traded over 72,652,546$ worth of Replimune Inc stock and bought 2,360,000 units worth 33,565,200$ . The most active insiders traders include Group, Llc Green Jeremy Red...、Capital Life Sciences Inves...、Jason P Rhodes. On average, Replimune Inc executives and independent directors trade stock every 21 days with the average trade being worth of 508,649$. The most recent stock trade was executed by Emily Luisa Hill on 16 August 2024, trading 8,938 units of REPL stock currently worth 90,989$.
replimune group, inc., a biotechnology company, develops oncolytic immune-gene therapies to treat cancer. it uses its proprietary immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. the company's lead product candidate is rp1, a selectively replicating version of herpes simplex virus 1, which is in phase i/ii clinical trials for a range of solid tumors; and that is in phase ii clinical trials for patients with cutaneous squamous cell carcinoma. it is also developing rp2, which is in phase i clinical trials for an anti-ctla-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by ctla-4; and rp3 to express immune-activating proteins that stimulate t cells. replimune group, inc. was founded in 2015 and is headquartered in woburn, massachusetts.
Replimune Inc executives and other stock owners filed with the SEC include: